Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0000905148-24-003291

Options or other derivatives

  • Chief Development Officer acquired 45,045 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Gamelin Erick · Chief Development Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-03-01 Grant or award : show line 1 in the form Stock Option (Right to Buy) +45,045 45,045 D
Loading xslF345X05/form4.xml…